NeoRx regulatory update

The FDA approved NERX's Verluma imaging agent to determine the stage of disease in patients with small cell lung cancer (SCLC). The product is composed of a monoclonal antibody fragment linked to technetium Tc 99.

Verluma is indicated for establishing the diagnosis of extensive disease in patients with newly diagnosed SCLC. According to President and CEO Paul Abrams, this positions the product as the first test to use in these patients. The label also notes that Verluma has been studied in other tumors. ...